COMP <GO>
BKD vs ABBV // EV/EBITDA & P/E VALUATION
Brookdale Senior Living Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BKD 0
— ABBV 12
▲ EV/EBITDA & P/E VALUATION LEADER: ABBV
LAST: $10.27 (+2.91%) • MKT CAP: $2.45B
valuation
34.6x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BKD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BKD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.20% | 70.20% | -44.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.30% | 29.00% | -28.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 34.6x | 33.3x | +1.30 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 3.47% | -2.80 | ABBV | /fcf-yield <GO> |
| Operating Margin | 0.40% | 24.60% | -24.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.20% | 6.90% | -15.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 8.60% | -6.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 65.1 | -16.74 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.45B | $513.86B | -$511.41B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BKD REV | ABBV REV | BKD GROSS % | ABBV GROSS % | BKD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.19B | $61.16B | 26.2% | 70.2% | $16.5M | $17.82B |
| FY 2024 | $3.13B | $56.33B | 25.6% | 70.0% | -$35.1M | $17.83B |
| FY 2023 | $3.02B | $54.32B | — | — | $162.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BKD // BETA —
ABBV // BETA 1.15